What the First Needle-Free Pediatric Mealtime Insulin Means for Families With Type 1 Diabetes

For Taisie Seigrist, mealtime insulin used to mean something most teenagers never have to think about: finding a private place to hide.

“Sometimes I would feel embarrassed when I had to take shots because I just felt different than everyone else,” she says. “I didn’t want to take it around people because I didn’t want anyone asking questions about why I’m taking shots. Around my friends I would usually go hide in the bathroom to take my shots instead of taking it around them because I was scared what they were going to say.”

Taisie's experience reflects what millions of families managing Type 1 diabetes navigate every day: not just the clinical demands of the disease, but the emotional and social weight that comes with it. Now, a new U.S. Food and Drug Administration (FDA) approval is offering a different path forward for children like her.

A New Option for Pediatric Diabetes Management

MannKind’s Afrezza, an ultra-rapid-acting inhaled mealtime insulin delivered through a small handheld inhaler, has received FDA approval for children and adolescents aged 6 and older, making it the first and only needle-free mealtime insulin approved for pediatric use. For families who have spent years managing injections, pump sites and the emotional toll that comes with both, the approval represents a meaningful shift in what diabetes management can look like.

Taisie and her mother, Jennifer Seigrist, participated in the clinical trial that supported the approval. The difference, Jennifer says, was immediate and profound.

“It was amazing to see her gain the confidence and the independence,” Jennifer says. “She wasn’t missing out on snacks or desserts or anything like that because she didn’t want to do another shot. She just kind of got to be a kid.”

The Emotional Side of Diabetes That People Don’t Always See

Before the trial, Taisie describes a daily routine defined by logistics and anxiety. She had to track needles, alcohol wipes and supplies at all times, while simultaneously managing school, friendships and the constant fear of being perceived as different. At one point, she says, she was even accused of taking injections for attention.

“It definitely hurt when people said that I was taking shots and had needles for attention, because I wasn’t,” she says. “I wish other teens understood that Type 1 diabetes isn’t something we choose to live with every day, and taking insulin isn’t a choice, it’s something that we have to do.”

Jennifer describes the unpredictability of living with a child whose blood sugar can require corrections multiple times overnight. “We don’t know if she’s going to have to get up three or four times at night to correct a high or a low,” she says. “Kids don’t understand how hard it is, and how much goes into it.”

What the Approval Means for Families

Taisie now takes one injection per day instead of the seven or eight she managed before. There is no additional device on her body, no pump, no site changes, just a small inhaler at mealtimes.

“Using inhaled insulin feels easier and more comfortable for me,” Taisie says. “It makes me feel more confident, especially at school or around friends. I can focus more on being a normal teenager and less on the stress of mealtime insulin.”

For families considering the option, Jennifer’s advice is straightforward: Talk to your endocrinologist. The family has been paying out of pocket since the trial ended because the impact was significant enough that stopping was not an option, though they are hopeful insurance coverage will follow the FDA approval.

Jennifer’s message to other parents is simple: “If you’re struggling with your kids, just talk to your doctor about it. It is worth a try. It may turn out to be life-changing for you as well.”